Miglustat
Back to searchMolecule Structure
Scientific Name
Miglustat
Description of the Drug
Miglustat is a glucosylceramide synthase inhibitor used for the management of mild to moderate type I Gaucher disease for patients who are not candidates for whole enzyme replacement.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00419
http://www.drugbank.ca/drugs/DB00419
Brand Name(s)
Zavesca
Company Owner(s)
Ani Pharmaceuticals Inc, Actelion Pharmaceuticals Us Inc, Breckenridge Pharmaceutical Inc, Edenbridge Pharmaceuticals Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Ceramide glucosyltransferase | SINGLE PROTEIN | INHIBITOR | CHEMBL2063 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL246893 | ||||||||
| PharmGKB | PA10140 | ||||||||
| Human Metabolome Database | HMDB0014563 | ||||||||
| DrugBank | DB00419 | ||||||||
| PubChem: Thomson Pharma | 14797912 | 14822645 | |||||||
| PubChem | 51634 | ||||||||
| LINCS | LSM-45962 | ||||||||
| Nikkaji | J258.518I | ||||||||
| PDBe | NBV | ||||||||
| BindingDB | 18355 | ||||||||
| EPA CompTox Dashboard | DTXSID6045618 | ||||||||
| DrugCentral | 1807 | ||||||||
| Brenda | 11067 | 167735 | 3896 | 232798 | 156331 | 7722 | 138681 | 29143 | 197536 |
| ChemicalBook | CB0125257 | ||||||||
| Guide to Pharmacology | 4841 | ||||||||
| rxnorm | ZAVESCA | MIGLUSTAT | |||||||
| PubChem: Drugs of the Future | 12014416 | ||||||||
| ChEBI | 50381 | ||||||||
| ZINC | ZINC000003794711 |
